- Home
- XSLL vs ABEO Comparison
XSLL vs ABEO Comparison
Compare XSLL & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
SELL
N/A
Current Price
$4.35
Company Overview
Basic Information| Metric | XSLL | ABEO |
|---|---|---|
| Founded | 2025 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.8M | 282.5M |
| IPO Year | 2025 | 2005 |
Fundamental Metrics
Financial Performance| Metric | XSLL | ABEO |
|---|---|---|
| Price | $10.01 | $4.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $18.88 |
| AVG Volume (30 Days) | 92.7K | ★ 1.0M |
| Earning Date | N/A | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $804.33 |
| Revenue Next Year | N/A | $119.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $9.80 | $4.00 |
| 52 Week High | $10.02 | $7.65 |
Technical Indicators
Market Signals| Indicator | XSLL | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 58.11 | 35.92 |
| Support Level | $9.95 | $4.27 |
| Resistance Level | N/A | $5.91 |
| Average True Range (ATR) | 0.01 | 0.23 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 75.00 | 10.83 |
Price Performance
Historical Comparison XSLL
ABEO
About XSLL Xsolla SPAC 1 Class A Ordinary Shares
Xsolla SPAC 1 is a blank check company.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.